BIP Wealth LLC raised its holdings in Amgen Inc. (NASDAQ: AMGN) by 808.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,872 shares of the medical research company's stock after buying an additional 8,785 shares during the period. BIP Wealth LLC's holdings

Amgen Inc. is rated a solid Buy, supported by robust revenue growth, pipeline strength, and recent FDA approvals despite looming patent expiries on legacy drugs. Tepezza's successful Phase 3 subcutaneous trial enhances its competitive position in the Thyroid Eye Disease - TED - market, targeting expanded patient access and chronic use. AMGN's 2026 guidance projects $37–$38.4bn in revenue and non-GAAP EPS of $21.6–$23, with a forward P/E of ~17x and a diverse late-stage pipeline.

Here is how Amgen (AMGN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen's subcutaneous Tepezza hits phase III goals in thyroid eye disease, matches IV efficacy and offers faster dosing that could expand access.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is currently developing its own treatment for the disease.

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction in Proptosis; Greater Than 3 mm THOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED).

Savvy Advisors Inc. grew its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 20.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,184 shares of the medical research company's stock after acquiring an additional 1,581 shares during

Buffalo Business and Estate Services Ltd. acquired a new position in Amgen Inc. (NASDAQ: AMGN) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 16,716 shares of the medical research company's stock, valued at approximately $5,471,000. Amgen accounts for approximately 0.8% of Buffalo